Qiagen N.V.
QGEN
Κατάταξη σε μετοχές
#2056
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Τιμή μετοχής
$48.85
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$10.07B
Αλλαγή (1 ημέρα)
4.96%
Αλλαγή (1 έτος)
0.61%
Χώρα
NL
Εμπόριο Qiagen N.V. (QGEN)
Κατηγορία
Healthcare
Κέρδη για την Qiagen N.V. (QGEN)
Κέρδη τον Jun 2026 TTM: $461.83M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Qiagen N.V., τα τρέχοντα κέρδη της εταιρείας είναι $461.83M. Το 2024, η εταιρεία παρουσίασε κέρδη $121.15M, μείωση σε σύγκριση με των κερδών του 2023 που ήταν $429.81M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Qiagen N.V. από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $461.83M | -5.80% |
| 2025 | $490.27M | 304.69% |
| 2024 | $121.15M | -71.81% |
| 2023 | $429.81M | -16.15% |
| 2022 | $512.60M | -18.09% |
| 2021 | $625.83M | 42.41% |
| 2020 | $439.47M | -665.05% |
| 2019 | $-77.78M | -134.45% |
| 2018 | $225.74M | 97.37% |
| 2017 | $114.38M | 100.98% |
| 2016 | $56.91M | -58.25% |
| 2015 | $136.30M | 14.17% |
| 2014 | $119.39M | 219.75% |
| 2013 | $37.34M | -74.28% |
| 2012 | $145.15M | 50.87% |
| 2011 | $96.21M | -44.42% |
| 2010 | $173.12M | 0.46% |
| 2009 | $172.33M | 44.47% |
| 2008 | $119.29M | 57.52% |
| 2007 | $75.73M | -28.61% |
| 2006 | $106.07M | 9.05% |
| 2005 | $97.26M | 33.81% |
| 2004 | $72.69M | 8.08% |
| 2003 | $67.26M | 73.05% |
| 2002 | $38.87M | -30.99% |
| 2001 | $56.32M | 43.94% |
| 2000 | $39.12M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $7.61B | 1,547.58% |
US
|
|
| $4.76B | 931.12% |
US
|
|
| $-252.70M | -154.72% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 259.01% |
US
|
